EPRX fundamentals
An in-depth look to EUPRAXIA PHARMACEUTICALS INC operating, investing, and financing activities
EPRX free cash flow for Q3 24 is -13.9 M CAD. For 2023, EPRX free cash flow was -28.02 M CAD and operating cash flow was -27.92 M CAD.
Q3 '19
Q4 '19
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
Q2 '24
Q3 '24
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CAD
Q3 '19
Q4 '19
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
Q2 '24
Q3 '24
TTM